tbuckley/cabot-search huggingface dataset:
Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups
Authors: Matthias Pinter, Bernhard Scheiner, Markus Peck-Radosavljevic
Journal: Gut (2020)

Following the success of immune checkpoint blockers (ICBs) in different cancer types, a large number of studies are currently investigating ICBs in patients with hepatocellular carcinoma (HCC), alone or in combination with other treatments. Both nivolumab and pembrolizumab, as well as the combination of nivolumab plus ipilimumab have been granted accelerated approval by the United States Food and Drug Administration for sorafenib-pretreated patients. While nivolumab and pembrolizumab both failed to meet their primary endpoints in phase III trials, the combination of atezolizumab plus bevacizumab eventually improved overall and progression-free survival compared with sorafenib in a front-line phase III trial, and thus, will become the new standard of care in this setting. Despite this breakthrough, there are patient populations with certain underlying conditions that may not be ideal candidates for this new treatment either due to safety concerns or potential lack of efficacy. In this review, we discuss the safety of ICBs in patients with pre-existing autoimmune disease, IBD or a history of solid organ transplantation. Moreover, we summarise emerging preclinical and clinical data suggesting that ICBs may be less efficacious in patients with underlying non-alcoholic steatohepatitis or HCCs with activated Wnt/β-catenin signalling.
Cardiac biomarkers predict one year mortality beyond concurrent comorbidity in elderly patients undergoing hip fracture surgery
Authors: S. Katsanos, N. Kafkas, C. Sardu, V. Kamperidis, A. Mavrogenis, P. Katsanou, J. Parissis, D. Farmakis, J. Lekakis, G. Filippatos
Journal: European Journal of Heart Failure (2015)
Novel method using small-caliber endoscope and balloon overtube for removing gastrointestinal residue
Authors: Kazuhiro Kozuka, Hideki Kobara, Noriko Nishiyama, Taiga Chiyo, Nobuya Kobayashi, Tatsuo Yachida, Tsutomu Masaki
Journal: Endoscopy (2020)

The presence of gastrointestinal blood clots and food residue often makes emergent endoscopic procedures difficult [1] [2]. Removal procedures are conventionally performed using grasping forceps, but these techniques require long procedure times and leave behind large amounts of residue. Although a tube-assisted suction method has been recently reported [3], the ability to pass through a narrow space and the adequacy of suction with side-scope navigation seem limited due to poor followability. For this reason, we developed a novel method of gastrointestinal residue removal using existing instruments.
Large granular lymphocytosis induced by dasatinib
Authors: Filipa Fernandes, Rita Ramalho, Rui Barreira, Margarida Silveira, Barbara J. Bain
Journal: American Journal of Hematology (2020)

A diagnosis of chronic myeloid leukemia, BCR-ABL1-positive, was made in a 66-year-old woman in 2016. She was treated with imatinib, 400 mg/daily, with initial response but 12 months later the cytogenetic response had been lost. Therapy was therefore changed to dasatinib, 100 mg/daily. Six months after the change of therapy her lymphocyte count, which had been normal, had increased to 6.54 × 109/L and by 18 months had risen further with peak counts of 7.5-7.7 × 109/L (bottom, Graph). The patient's blood film showed that the lymphocytosis was largely due to an increase of large granular lymphocytes. These were mainly cytologically normal, often with large, prominent granules (top left, top right Images), but a minority showed dysplastic features, such as nuclear lobulation (bottom left Image). A minor population showed features resembling those seen in viral infections (bottom right Image). A bone marrow aspirate showed 28% lymphocytes, mainly small lymphocytes, which had less obvious cytoplasmic granules. Peripheral blood immunophenotyping showed 24% of leucocytes to have the immunophenotype of natural killer (NK) cells: CD3−/CD16+/CD56+; most expressed CD2 but 9% of this population did not. Molecular evaluation showed an IS BCR-ABL1 of 0.06%, the lowest value obtained since the beginning of dasatinib therapy. Large granular lymphocytosis is a well recognized feature of dasatinib therapy. It may occur in as many as a third to a half of patients on this drug.1, 2 Both T cells and NK cells can be increased. Rearrangement of T-cell receptor genes can indicate monoclonality or oligoclonality of both T cells and NK cells, with a small clone being present at diagnosis and expanding during dasatinib therapy.1 This phenomenon may be associated with higher response rates, longer response durations, and increased overall survival.1, 2 The authors declare no conflict of interest with the content of the paper. Data sharing not applicable to this article as no datasets were generated or analysed during the current study
SARS CoV-2 infection among patients using immunomodulatory therapies
Authors: Kevin L Winthrop, Amanda E Brunton, Susan Beekmann, Philip Polgreen, John Baddley, Kenneth G Saag, Cassandra Calabrese, Leonard Calabrese, Philip C Robinson, Zachary S Wallace, Jeffrey R Curtis
Journal: Annals of the Rheumatic Diseases (2020)

Table 1 COVID-19 outcomes among autoimmune patients receiving immunomodulatory therapy Autoimmune cohort Anti-TNF* biologic with/ without DMARDs † and/ or corticosteroids (n=16) Biologic ‡ (non-TNF) with/ without DMARDs and/or corticosteroids (n=15) Non-biologic DMARDs alone (n=11) Non-biologic DMARDs and corticosteroids (n=3) Corticosteroids § alone (n=9) JAK inhibitor ¶ (n=3) Other**immunemodulatory therapy with/ without DMARDs and/or corticosteroids (n=11) Post solid organ transplant (n=13) Female (%) 56.3 66.7 81.8 66.7 33.3 66.7 72.
Re-Engage: A Novel Nurse-Led Program for Survivors of Childhood Cancer Who Are Disengaged From Cancer-Related Care
Authors: Christina Signorelli, Claire E. Wakefield, Karen A. Johnston, Joanna E. Fardell, Jordana K McLoone, Mary-Ellen E. Brierley, Maria Schaffer, Elysia Thornton-Benko, Afaf Girgis, W. Hamish Wallace, Richard J. Cohn, _ _
Journal: Journal of the National Comprehensive Cancer Network (2020)

Background: Survivors of childhood cancer often experience treatment-related chronic health conditions. Survivorship care improves survivors’ physical and mental health, yet many are disengaged from care. Innovative models of care are necessary to overcome patient-reported barriers to accessing survivorship care and to maximize survivors’ health. Methods: We piloted a novel survivorship program, called “Re-engage,” a distance-delivered, nurse-led intervention aiming to engage, educate, and empower survivors not receiving any cancer-related care. Re-engage involves a nurse-led consultation delivered via telephone/online to establish survivors’ medical history and needs. Participants completed questionnaires at baseline, 1 month postintervention, and 6-month follow-up. Results: A total of 27 survivors who had not accessed survivorship care in the last 2 years participated (median age, 31 years; interquartile range [IQR], 27–39 years); of which, 82% were at high-risk for treatment-related complications. Participation in Re-engage was high (75%) and there was no attrition once survivors enrolled. At 1 month postintervention, 92% of survivors reported that Re-engage was “beneficial,” which all survivors reported at 6-month follow-up. Survivors’ overall satisfaction with their care increased from 52% before Re-engage to 84% at 1 month postintervention. Survivors’ mean self-efficacy scores remained similar from baseline to 1 month postintervention ( b = −0.33, 95% CI, −1.31 to 0.65), but increased significantly from baseline to 6-month follow-up ( b = 1.64, 95% CI, 0.28–3.00). At 6-month follow-up, 73% of survivors showed an increase in health-related self-efficacy compared with baseline. Conclusions: Re-engage is a highly acceptable and feasible intervention and promotes health-related self-efficacy, which is integral to survivors being advocates for their own health. Further empirical work is needed to evaluate the long-term efficacy of Re-engage. Trial registration: ACTRN12618000194268
Clinical development of immuno-oncology in China
Authors: Da-Wei Wu, Hui-Yao Huang, Yu Tang, Yang Zhao, Zhi-Min Yang, Jun Wang, Shu-Hang Wang, Yue Yu, Yuan Fang, Hong Fang, Ying Bai, Chao Sun, Qi Fan, An-Qi Yu, Huan-Ling Wang, Chun-Xia Du, Kun Chen, Ming-De Huang, Yin Zhang, Ning Li, Bing-He Xu, Yan Sun, Jie He
Journal: The Lancet Oncology (2020)
Long Term Follow up after Adoptive Transfer of CD19-Specific CAR+ T Cells Genetically Modified Via Non-Viral Sleeping Beauty S ystem Following Hematopoietic Stem Cell Transplantation (HSCT)
Authors: Partow Kebriaei, Helen Huls, Simon Olivares, Aaron F Orozco, Shihuang Su, Sourindra N Maiti, Elenanor De Groot, Amy Smith, Yijun Yang, Gabriela Rondon, Muzaffar H. Qazilbash, Stefan O. Ciurea, Amin M. Alousi, Yago Nieto, David Costa Marin, Uday Popat, Chitra Hosing, Hagop M. Kantarjian, Katayoun Rezvani, Elizabeth J Shpall, Richard E Champlin, Laurence J N Cooper, Harjeet Singh
Journal: Blood (2017)
Covid-19: Mental health and economic problems are worse in US than in other rich nations
Authors: Janice Hopkins Tanne
Journal: BMJ (2020)

Covid-19 has caused mental health problems, economic hardship, and lack of trust in national leadership among about a third of US adults, higher rates than in nine other high income countries, a survey by the Commonwealth Fund shows. 1The private foundation's president, David Blumenthal, a coauthor of the report, said, "People in other countries are living a different, better, reality.Americans should realise that our country can do better, too.We can start by ensuring everyone can get and afford the healthcare they need, and by implementing public health measures such as mask wearing, social distancing, and robust testing and tracing that can help us stop covid-19, as so many others have effectively accomplished."He said the pandemic was a unique time to make these comparisons because all countries were facing the same crisis at the same time.The Commonwealth Fund is a non-profit foundation that supports health policy reform and a high performance health system.Reginald Williams II, lead author of the report and a fund vice president, said, "In the US the pandemic has taken a greater toll on people's wellbeing when compared with other high income countries."He said that as cases and deaths continued to increase, US policymakers "should look abroad for innovative solutions."Clear, consistent messages about the pandemic, with avoidance of politicising and coordination of testing, provision of supplies, and contact tracing, were needed to combat the pandemic, said Eric Schneider, a coauthor and fund vice president.
Coroner warns about poor drug reviews after patient dies from tramadol overdose
Authors: Clare Dyer
Journal: BMJ (2020)

A senior coroner has demanded action by Simon Stevens, chief executive of NHS England, to ensure that GPs monitor repeat prescriptions properly, after an 84 year old man with dementia died from an overdose of tramadol.

Peter Cole, who was found collapsed at his home in Welwyn in Hertfordshire by a neighbour, had amassed a large quantity of unused prescription drugs at his house. He had numerous drugs on repeat prescription, said Geoffrey Sullivan, chief coroner for Hertfordshire. One was the opiate painkiller tramadol, for which he had had a repeat …
Abstract A20: Single-cell immune TCR repertoire profiling in the context of immunotherapy by using three 10x Genomics libraries
Authors: Yuan Qi, Jin Seon Im, Xiaoping Su
Journal: Cancer Research (2020)

Abstract 10x Genomics single-cell sequencing provides a comprehensive and scalable solution for cell characterization and gene expression profiling of hundreds to tens of thousands of cells. For performance comparison of single-cell immune TCR repertoire profiling, we tested three libraries: (1) 5-prime gene expression, (2) direct enrichment for TCR, and (3) post-cDNA-amplification enrichment for TCR, on two invariant natural killer T (iNKT) cells, on B240 and B241, with iNKT purity at 90% and 45%, respectively. We also performed correlation analysis between gene expression data and clonotype data by library 3. About 1,100 cells of B240 and 580 cells of B241 were sequenced. The numbers of productive clonotypes of B240 were identified as 165, 284, and 332 for the three libraries, respectively, while 47 clonotypes overlapped among the libraries. The numbers of productive clonotypes of B241 were 88, 152, and 148, respectively, while 35 clonotypes overlapped. Each sample is a mixture of iNK T cells and non-invariant NK T cells. We were able to identify the clusters of iNKT cells using the 5’ gene expression data by library 1 in tSNE plots for both B240 and B241. More importantly, the clusters correlated strongly with the TCR clonotypes identifying iNKT cells by library 3. Based upon our data, we noticed that the number of clonotypes identified is proportional to the number of cells sequenced regardless of libraries. Library 1 has low sensitivity in terms of clonotype detection, due to un-enrichment of TCR genes, and mainly detected single chain in each cell (beta chain most of the time). The other two libraries are able to identify high and similar number of clonotypes. However, library 3 is able to associate gene expression pattern with TCR clonotype usage, which is a big advantage over the other two libraries for 10x Genomics single-cell immune TCR repertoire profiling. Note: This abstract was not presented at the conference. Citation Format: Yuan Qi, Jin Seon Im, Xiaoping Su. Single-cell immune TCR repertoire profiling in the context of immunotherapy by using three 10x Genomics libraries [abstract]. In: Proceedings of the AACR Special Conference on the Advances in Pediatric Cancer Research; 2019 Sep 17-20; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Res 2020;80(14 Suppl):Abstract nr A20.
The Little Lies
Authors: Michelle M. Kittleson
Journal: Annals of Internal Medicine (2020)

Ad Libitum4 August 2020The Little LiesMichelle M. Kittleson, MD, PhDMichelle M. Kittleson, MD, PhDSmidt Heart Institute, Cedars-Sinai, Los Angeles, California (M.M.K.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M19-1773 Audio Reading - “The Little Lies” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “The Little Lies” by Michelle M. Kittleson, MD, PhD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Are they forgiven,The little lies I tell theOnes I care about?To amuse my son:Hold a conch shell to your earAnd hear the ocean.To calm my husband:Dented fender? Must have beenAt the airport lot.To please my old friend:Ten years and you look the same—Tell me your secret!To quell a boy's tears:Yes, your dad is sick. Yes, IPromise to save him.But truth will out. KidsRealize shells just amplifyThe ambient sounds.Husbands discoverWho really dented the car;Friends know they look old.Kids, husbands, and friends,Understand the impetus,Forgive my white lies.Boy, towheaded, wide-eyed as... Author, Article, and Disclosure InformationAffiliations: Smidt Heart Institute, Cedars-Sinai, Los Angeles, California (M.M.K.)Current Author Address: Michelle M. Kittleson, MD, PhD, 8536 Wilshire Boulevard, Suite 301, Los Angeles, CA 90211; e-mail, michelle.[email protected]org. PreviousarticleNextarticle Advertisement Audio Reading - “The Little Lies” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “The Little Lies” by Michelle M. Kittleson, MD, PhD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 4 August 2020Volume 173, Issue 3Page: 251 ePublished: 4 August 2020 Issue Published: 4 August 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
No Influence of BCR-ABL1 Transcript Types e13a2 and e14a2 on MR4.5 in Patients with Chronic Myeloid Leukemia Treated with Nilotinib Frontline
Authors: Alexis Genthon, Franck Emmanuel Nicolini, Marc G. Berger, Sandrine Saugues, Alexandre Janel, Denis Guyotat, Sandrine Hayette, Lydia Campos, Pascale Flandrin-Gresta
Journal: Blood (2017)
Injectable ferrimagnetic silk fibroin hydrogel for magnetic hyperthermia ablation of deep tumor
Authors: Kun-Yu Qian, Yonghong Song, Xu Yan, Liang Dong, Jingzhe Xue, Yunjun Xu, Bao Wang, Baoqiang Cao, Qingbing Hou, Wei Peng, Jinlong Hu, Kun Jiang, Sheng Chen, Huiqing Wang, Yang Lu
Journal: Biomaterials (2020)
Cyclodextrin-mediated formation of porous RNA nanospheres and their application in synergistic targeted therapeutics of hepatocellular carcinoma
Authors: Xiaoxia Chen, Tianshu Chen, Lili Zhang, Zhenyu Wang, Qingqing Zhou, Tingting Huang, Chao Ge, Huili Xu, Miaoxin Zhu, Fangyu Zhao, Ming Yao, Hua Tian, Hong Li, Xiaoli Zhu, Jinjun Li
Journal: Biomaterials (2020)
Tachycardia in a Patient With Heart Failure
Authors: Naga Venkata Pothineni, Swathi Kovelamudi, Hakan Paydak
Journal: JAMA Internal Medicine (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial—comment on: ‘Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus’ by Chatzidionysiou<i>et al</i>
Authors: Alessandra Bettiol, Francesca Pregnolato, Savino Sciascia, Giacomo Emmi, Domenico Prisco, Pier Luigi Meroni
Journal: Annals of the Rheumatic Diseases (2020)

We read with interest the article by Chatzidionysiou et al ,1 which reported a post-hoc analysis of two trials on intravenous belimumab in systemic lupus erythematosus (SLE), showing a significant reduction of antiphospholipid antibodies (aPL) only in patients cotreated with antimalarials.

However, this post-hoc analysis focused on anticardiolipin antibodies (aCL) only, with no data on anti-β2-glycoprotein I (antiβ2GPI) antibodies, which display the best diagnostic/prognostic value in antiphospholipid antibodies syndrome (APS). Moreover, although long-term use of antimalarials was reported to reduce aPL levels by itself,2 no information on the duration of antimalarials cotreatment was reported.1 Interestingly, treatment with belimumab was recently reported to induce aCL and antiβ2GPI disappearance in a small case series of patients with SLE-associated APS.3 We also reported a significant reduction in aCL and antiβ2GPI titres in 12 patients with SLE on belimumab, either alone or associated with antimalarials.4

This study aimed to assess the effect of subcutaneous belimumab (200 mg/week) versus placebo, in association with standard therapy +/- antimalarials, on aCL and antiβ2GPI titers in patients with SLE, …
Five-Year Outcomes with Transcatheter Aortic-Valve Replacement
Authors: Fabio Barili, Nicholas Freemantle, Alessandro Parolari
Journal: New England Journal of Medicine (2020)

The key message of the report by Makkar et al. 1 and the editorial by Van Belle 2 (Feb.27 issue) on the Placement of Aortic Transcatheter Valves (PARTNER) 2 cohort A trial is the effectiveness of transcatheter aortic-valve replacement (TAVR) in terms of death from any cause or disabling stroke at 5 years.Nonetheless, on critical appraisal, other important results are noted.The landmark analysis of events occurring between 2 and 5 years after the procedure (Fig. S4 in the Supplementary Appendix of the article, available at NEJM.org) shows that TAVR was associated with a higher risk of death or disabling stroke after 2 years than was surgical aortic-valve replacement, with a hazard that was 27% higher.Moreover, the intersection of the time-to-event curves (Fig. 1 of the article) and the wide differences between the hazard ratio at 0 to 2 years (0.89; 95% confidence interval [CI], 0.73 to 1.09) and that at 2 to 5 years (1.27; 95% CI, 1.06 to 1.53) suggest that the hazards were not constant over time.Therefore, the reported 5-year hazard ratio is not an accurate reflection of the findings, which require landmark analysis or time-varying modeling. 3,4 The key message of the trial is also overshadowed by the disadvantage of TAVR in terms of reoperations and rehospitalization, which underscores concerns about the durability of TAVR devices.In summary, the 5-year results from the PARTNER 2 cohort A trial are not a swan song for surgery.